Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.
She has a BA in English language and literature from Rutgers University. You can connect with Julia on LinkedIn.
Net Results Vary When Using Cell-Free DNA Blood Tests for CRC Screening
Results could vary between having a net benefit or harm based on the balance between achieving screening in individuals who otherwise wouldn’t and using cell-free DNA blood tests in favor of more effective methods of screening for colorectal cancer (CRC).
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Cost Effectiveness Varies in TAS-102 Plus Bevacizumab Third Line Treatment
Patients with refractory metastatic colorectal cancer could use trifluridine/tipiracil (TAS-102) plus bevacizumab as a cost effective third line treatment in China but the same was not found in the United States and United Kingdom.
New FTC Lawsuit Against PBMs Has Broad Implications for Pharmaceuticals, Ted Okon Says
Ted Okon, MBA, executive director of the Community Oncology Alliance, spoke with The American Journal of Managed Care® about how the Federal Trade Commission's (FTC) lawsuit against pharmacy benefit managers (PBMs) could affect the future of pharmaceuticals and oncology.
2 Commerce Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.